Immunologists are delighted that the field of innate immunity has been recognized by this year's Nobel Prize in Physiology or Medicine. However, we believe that the Nobel Committee should also have acknowledged the seminal contributions of immunologists Charles A. Janeway Jr (1943–2003) and Ruslan Medzhitov.
Janeway laid out the major theory that unifies the principles of innate and adaptive immunity (C. A. Janeway Cold Spring Harb. Symp. Quant. Biol. 54, 1–13; 1989), later experimentally verified with Medzhitov and then by many others. He recognized that antigen alone is insufficient to elicit an adaptive immune response, and postulated that both primitive and higher animals have specialized 'pattern-recognition receptors' that induce the innate immune response when activated by a particular class of conserved microbial products ('pathogen-associated molecular patterns').
The most important tenet of his theory was the connection between innate immune signalling and initiation of the adaptive immune response through enhancement of antigen processing and presentation, induction of co-stimulatory signals and cytokine release.
Medzhitov and Janeway subsequently cloned a human 'Toll-like' receptor and showed that it activated signalling pathways that induce adaptive immunity (R. Medzhitov et al. Nature 388, 394; 1997). This remarkable demonstration also provided a framework for interpreting the significance of Toll-like receptors and their ligands for the immune response.
The innate–adaptive connection is now a fundamental principle in immunology. We believe that the work of Janeway and Medzhitov was a Nobel-standard breakthrough for immunology.
Author information
Affiliations
Corresponding author
Supplementary information
Rights and permissions
About this article
Cite this article
Allison, J., Benoist, C. & Chervonsky, A. Nobels: Toll pioneers deserve recognition. Nature 479, 178 (2011). https://doi.org/10.1038/479178a
Published:
Issue Date:
Further reading
-
Living in a Hostile World: Inflammation, New Drug Development, and Coronavirus
Frontiers in Immunology (2021)
-
Receptor-ligand based molecular interaction to discover adjuvant for immune cell TLRs to develop next-generation vaccine
International Journal of Biological Macromolecules (2020)
-
Application of built-in adjuvants for epitope-based vaccines
PeerJ (2019)
-
Is the Nobel Prize good for science?
The FASEB Journal (2013)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.